ganitumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 458275232

| type = mab

| image =

| alt =

| mab_type = mab

| source = u

| target = IGF-1R

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 905703-97-1

| ATC_prefix = none

| ATC_suffix =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = CK1441RCZ8

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| C=6472 | H=10028 | N=1728 | O=2020 | S=42

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| KEGG_Ref = {{keggcite|changed|kegg}}

| KEGG = D09908

}}

Ganitumab is a human monoclonal antibody against type 1 insulin-like growth factor receptor (IGF1R), designed for the treatment of cancers.{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ganitumab|publisher=American MedicaAssociation|url=http://www.ama-assn.org/resources/doc/usan/ganitumab.pdf}}{{cite journal | vauthors = Martínez P, Sales Fidalgo PA, Felip E | title = Ganitumab for the treatment of small-cell lung cancer | journal = Expert Opinion on Investigational Drugs | volume = 23 | issue = 10 | pages = 1423–32 | date = October 2014 | pmid = 25189625 | doi = 10.1517/13543784.2014.951434 | s2cid = 7318164 }}

Ganitumab was developed by Amgen. A phase III clinical trial (for metastatic pancreatic cancer) was abandoned in August 2012.{{cite news|url=http://news.sciencemag.org/scienceinsider/2012/08/amgen-pulls-cancer-drug.html?ref=em |title=Amgen Pulls Cancer Drug |date=10 Aug 2012 |url-status=dead |archive-url=https://web.archive.org/web/20130723163332/http://news.sciencemag.org/scienceinsider/2012/08/amgen-pulls-cancer-drug.html?ref=em |archive-date=2013-07-23 }}{{cite news

|url=http://www.istockanalyst.com/finance/story/5984012/amgen-amgn-terminates-ganitumab-pancreatic-cancer-trial

|title=Amgen (AMGN) Terminates Ganitumab Pancreatic Cancer Trial

|date=8 Aug 2012

|url-status=dead

|archive-url=https://web.archive.org/web/20120810222244/http://www.istockanalyst.com/finance/story/5984012/amgen-amgn-terminates-ganitumab-pancreatic-cancer-trial

|archive-date=2012-08-10

}}